IL15 can reverse the unresponsiveness of wilms' tumor antigen-specific CTL in patients with prostate cancer

Clinical Cancer Research

Volumn 15, Issue 4, 2009, Pages 1145-1154

  King, Judy W ^a   Thomas, Sharyn ^a   Corsi, Fabrizio ^c   Gao, Liquan ^a   Dina, Roberto ^b   Gillmore, Roopinder ^a   Pigott, Katharine ^a   Kaisary, Amir ^a   Stauss, Hans J ^a   Waxman, Jonathan ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c UNIVERSITY OF FOGGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; HLA A2 ANTIGEN; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 7; MELAN A; TUMOR ANTIGEN; UNCLASSIFIED DRUG; WILMS TUMOR ANTIGEN 1; WT1 PROTEIN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NEPHROBLASTOMA; PRIORITY JOURNAL; PROSTATE CANCER; CELL CULTURE; DRUG EFFECT; IMMUNOLOGY; MIDDLE AGED; PHYSIOLOGY; PROSTATE TUMOR;

ADULT; AGED; CELLS, CULTURED; HLA-A2 ANTIGEN; HUMANS; INTERLEUKIN-15; INTERLEUKIN-2; INTERLEUKIN-7; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; WT1 PROTEINS;

EID: 63149193395     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1821     Document Type: Article

References (43)

1. Gronberg H. Prostate cancer epidemiology. Lancet 2003:361:859-64.
2. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008:358: 1250-61.
3. Kast WM, Offringa R, Peters PJ, et al. Eradication of adenovirus E1-induced tumors by E1A-specific cytotoxic! lymphocytes. Cell 1989;59:603-14.
4. Inoue K, Ogawa H, Sonoda Y, et al. Aberrant overex- pression of the Wilms tumor gene (WT1) in human leukemia. Blood 1997;89:1405-12.
5. Loeb DM, Evron E, Patel CB, et al. Wilms'tumor suppressor gene (WT1) is expressed in primary breast tumors despite tumor-specific promoter methylation. Cancer Res 2001:61:921 -5.
6. Oji Y, Ogawa H, Tamaki H, et al. Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth. Jpn J Cancer Res 1999;90: 194-204.
7. Shimizu M, Toki T, Takagi Y, Konishi I, Fujii S. Immuno-histochemical detection of the Wilms' tumor gene (WT1) in epithelial ovarian tumors. Int J Gynecol Pathol 2000:19:158-63.
8. Koesters R, Linnebacher M, Coy JF, et al. WT1 is a tumor-associated antigen in colon cancer that can be recognized by in vitro stimulated cytotoxicTcells. Int J Cancer 2004;109:385-92.
9. Bergmann L, Miething C, Maurer U, et al. High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome. Blood 1997;90:1217-25.
10. Miyoshi Y Ando A, Egawa C, et al. High expression of Wilms' tumor suppressor gene predicts poor prognosis in breast cancer patients. Clin Cancer Res 2002; 8:1167-71.
11. Yamagami X Sugiyama H, Inoue K, et al. Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: implications for the involvement of WT1 in leukemogenesis. Blood 1996;87:2878-84.
12. Zapata-Benavides P, Tuna M, Lopez-Berestein G.Tari AM. Downregulation of Wilms'tumorl protein inhibits
13. breast cancer proliferation. Biochem Biophys Res Commun 2002;295:784-90.
14. Xue SA, Gao L, Hart D, et al. Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene- transduced humanTcells. Blood 2005;106:3062-7.
15. Bodinier M, Peyrat MA,Tournay C, et al. Efficient detection and immunomagnetic sorting of specificTcells using multimers of MHC class I and peptide with reduced CDS binding. Nat Med 2000;6:707-10.
16. DeMars R, Chang CC, Shaw S, Reitnauer BJ, Son- del PM. Homozygous deletions that simultaneously eliminate expressions of class I and class II antigens of EBV-transformed B-lymphoblastoid cells. I. Reduced proliferative responses of autologous and allogeneic Tcells to mutant cells that have decreased expression of class II antigens. Hum Immunol 1984; 11:77-97.
17. Sukov WR, Cheville JC, Lager DJ, Lewin JR. Sebo TJ, Lewin M. Malignant mixed epithelial and stromal tumor of the kidney with rhabdoid features: report of a case including immunohistochemical, molecular genetic studies and comparison to morphologically similar renal tumors. Hum Pathol 2007;38:1432-7.
18. Barisoni L, Madaio MP, Eraso M, Gasser DL, Nelson PJ. The kd/kd mouse is a model of collapsing glomerulopathy. J Am Soc Nephrol 2005;16:2847-51.
19. Krausa P, Brywka M III, Savage D, et al. Genetic polymorphism within HLA-A*02: significant allelic variation revealed in different populations. Tissue Antigens 1995;45:223-31.
20. LeeTD. Distribution of HLA antigens in North American Caucasians, North American Blacks and Orientals. New York: Springer-Verlag; 1990.
21. Gao L, Bellantuono I, Elsasser A, et al. Selective elimination of leukemic CD34(+) progenitor cells by cytotoxicT lymphocytes specific for WT1. Blood 2000;95:2198-203.
22. Teague RM, Sather BD, Sacks JA, et al. Interleukin- 15 rescues tolerant CD8+ Tcells for use in adoptive immunotherapy of established tumors. Nat Med 2006;12:335-41.
23. Bendle GM, Xue SA, Holler A, Stauss HJ. A study of T cell tolerance to the tumor-associated antigen
24. MDM2: cytokines can restore antigen responsiveness, but not high avidity T cell function. PLoS ONE 2007;2:e353.
25. Klebanoff CA, Finkelstein SE, Surman DR, et al. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ Tcells. Proc Natl Acad Sci U S A 2004;101:1969-74.
26. Roychowdhury S, May KF, Jr., Tzou KS, et al. Failed adoptive immunotherapy with tumor-specific T cells: reversal with low-dose interleukin 15 but not low-dose interleukin 2. Cancer Res 2004;64: 8062-7.
27. Brentjens RJ, Latouche JB, Santos E, et al. Eradication of systemic B-cell tumors by genetically targeted humanT lymphocytes co-stimulated by CD80 and in- terleukin-15. Nat Med 2003;9:279-86.
28. Devilard E, Bladou F, Ramuz O, et al. FGFR1 and WT1 are markers of human prostate cancer progression. BMC Cancer 2006:6:272.
29. Marcet-Palacios M, Ulanova M, Duta F, et al. The transcription factor Wilms tumor 1 regulates matrix metalloproteinase-9 through a nitric oxide-mediated pathway. J Immunol 2007;179:256-65.
30. Ye Y, Raychaudhuri B, Gurney A, Campbell CE, Williams BR. Regulation of WT1 by phosphorylation: inhibition of DNA binding, alteration of transcriptional activity and cellular translocation. EMBO J 1996;15: 5606-15.
31. Sakamoto YYoshida M, Semba K, HunterT Inhibition of the DNA-binding and transcriptional repression activity of the Wilms' tumor gene product, WT1, by cAMP-dependent protein kinase-mediated phosphorylation of Ser-365 and Ser-393 in the zinc finger domain. Oncogene 1997;15:2001-12.
32. Weinzierl AO, Maurer D, Altenberend F, et al. A cryptic vascular endothelial growth factor T-cell epitope: identification and characterization by mass spectrometry and T-cell assays. Cancer Res 2008;68: 2447-54.
33. Scheibenbogen C, Letsch A,Thiel E, et al. CDS T- cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood 2002;100:2132-7.
34. Rezvani K, Grube M, Brenchley JM, et al. Functional leukemia-associated antigen-specific memory CD8+ Tcells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. Blood 2003;102:2892-900.
35. Rezvani K, Yong AS, Savani BN, et al. Graft- versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia. Blood 2007;110:1924-32.
36. Oka XTsuboi A. Taguchi T, et al. Induction of WT1 (Wilms' tumor gene) -specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer re gression. Proc Natl Acad Sci U S A 2004;101: 13885-90.
37. Rezvani K. Yong AS, Mielke S, et al. Leukemia- associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 2008;111:236-42.
38. Asemissen AM, Keilholz U. Tenzer S, et al. Identification of a highly immunogenic HLA-A*01-bindingTcell epitope of WT1. Clin Cancer Res 2006;12:7476-82.
39. Beverly B, Kang SM, Lenardo MJ, Schwartz RH. Reversal of in vitro Tcell clonal anergy by IL-2 stimulation. Int Immunol 1992;4:661-71.
40. Zippelius A, Batard P, Rubio-GodoyV, et al. Effector function of human tumor-specific CDS Tcells in melanoma lesions: a state of local functional tolerance. Cancer Res 2004;64:2865-73.
41. Lee PP, Yee C, Savage PA, et al. Characterization of circulating Tcells specific for tumor-associated antigens in melanoma patients. Nat Med 1999;5:677-85.
42. Willimsky G, Blankenstein T. Sporadic immunogenic tumours avoid destruction by inducingT-cell tolerance. Nature 2005;437:141 -6.
43. Bendle GM, Holler A, Pang LK, et al. Induction of unresponsiveness limits tumor protection by adoptively transferred MDM2-specific cytotoxic T lymphocytes. Cancer Res 2004;64:8052-6.